Mode
Text Size
Log in / Sign up

Lung Infection

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Lung Infection

4 trials tracked for Lung Infection: 2 in phase 3 or 4.

4Trials tracked
2Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 2 Phase 2 2
  1. Phase 3 Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia Completed
  2. Phase 3 Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa Completed
  3. Phase 2 Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis Completed
  4. Phase 2 Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.